# Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

> **NCT03780517** · PHASE1 · COMPLETED · sponsor: **Boston Pharmaceuticals** · enrollment: 117 (actual)

## Conditions studied

- Advanced Nonhaematologic Malignancies

## Interventions

- **DRUG:** BOS172738

## Key facts

- **NCT ID:** NCT03780517
- **Lead sponsor:** Boston Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-12
- **Primary completion:** 2023-09-26
- **Final completion:** 2023-09-26
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2023-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03780517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03780517, "Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03780517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*